Nicollet Investment Management Inc. bought a new stake in Alkermes Plc (NASDAQ:ALKS) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 26,710 shares of the company’s stock, valued at approximately $1,462,000.

Several other institutional investors and hedge funds have also made changes to their positions in ALKS. Toronto Dominion Bank raised its position in shares of Alkermes by 12.7% in the 2nd quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock valued at $109,000 after purchasing an additional 212 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Alkermes in the 4th quarter valued at approximately $114,000. Quantbot Technologies LP acquired a new position in shares of Alkermes in the 3rd quarter valued at approximately $126,000. Virtu Financial LLC acquired a new position in shares of Alkermes in the 3rd quarter valued at approximately $201,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Alkermes in the 3rd quarter valued at approximately $214,000. 99.31% of the stock is currently owned by institutional investors.

A number of brokerages have issued reports on ALKS. Credit Suisse Group set a $66.00 target price on Alkermes and gave the company a “buy” rating in a research report on Tuesday, November 28th. Zacks Investment Research raised Alkermes from a “hold” rating to a “buy” rating and set a $61.00 target price on the stock in a research report on Monday, January 8th. Barclays lowered Alkermes from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $66.00 to $50.00 in a research report on Monday, October 16th. JPMorgan Chase & Co. set a $78.00 target price on Alkermes and gave the company a “buy” rating in a research report on Friday, October 27th. Finally, UBS Group set a $54.00 target price on Alkermes and gave the company a “hold” rating in a research report on Friday, October 27th. Eight investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Alkermes has an average rating of “Hold” and an average price target of $64.17.

Shares of Alkermes Plc (NASDAQ:ALKS) opened at $56.00 on Thursday. Alkermes Plc has a twelve month low of $46.42 and a twelve month high of $64.04. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.05 and a quick ratio of 2.72. The firm has a market capitalization of $8,559.17, a P/E ratio of -50.45 and a beta of 1.94.

In related news, insider Shane Cooke sold 72,793 shares of the company’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $60.55, for a total transaction of $4,407,616.15. Following the completion of the transaction, the insider now directly owns 147,501 shares in the company, valued at approximately $8,931,185.55. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Iain Michael Brown sold 10,652 shares of the company’s stock in a transaction on Friday, December 29th. The stock was sold at an average price of $54.81, for a total value of $583,836.12. The disclosure for this sale can be found here. Insiders sold a total of 135,485 shares of company stock valued at $8,227,502 over the last quarter. Company insiders own 5.34% of the company’s stock.

WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/nicollet-investment-management-inc-invests-1-46-million-in-alkermes-plc-alks/1852507.html.

About Alkermes

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes Plc (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.